Envista Holdings Corp Q4 FY2024 earnings call

• Q4 Results: Core growth 2% and adjusted EBITDA margin ~14%. Implants business improved, Spark had gross margin improvement and operational improvements. Global dental market soft but stable with headwinds in specific geographies.
• 2024 Performance: Year of transition, refreshed leadership, took actions to support performance, delivered against 2024 guidance. Core growth in adjusted EBITDA negative 1.5% and 11.8%, generated over $300M free cash flow (35% increase vs prior year).
• 2025 Guidance: Core growth 1%-3%, adjusted EBITDA margin ~14%, EPS $0.95-$1.05. Restructuring to generate ~$20M annualized savings, $250M share repurchase authorized.
• Growth Initiatives: Invested $25M to accelerate growth in high-margin businesses like Nobel Biocare; Spark grew double-digits in 2024 with consecutive quarter-on-quarter gross margin improvement; launched new products/platforms.
• Operational Improvements: Envista Business System drove efficiency, e.g., cutting Spark customer setup times in half, unit costs by over 25%, double-digit productivity gains in Nobel Biocare plant, double-digit reduction in consumables inventory.
• People Investments: Refreshed senior team, invested in engagement/talent development, supported Envista Smile project with over $2M in 2024, reduced recordable safety incidents, increased employee feedback survey participation.

Specialty Products & Technologies Segment: Core revenue declined 40 basis points year-over-year. Orthodontics: Spark continued well, but brackets/wires down mid-single digits in Q4 due to China's VBP preparations; excluding China, brackets/wires up low-single digits, aligner business (Spark) grew double-digits. Implants: Fourth straight quarter of growth for Challenger and third consecutive quarter of improvement for Nobel in North America. Equipment & Consumables Segment: Core sales increased 6.4% year-on-year. Dental consumables had high teens growth in Q4, but low single-digits excluding the favorable comp from the 2023 cyber attack; Diagnostics declined, China had sharp declines, North America declined mid-single digits. Adjusted operating margin increased 570 basis points mainly due to higher consumable volumes and FX transaction gains, partially offset by investments.

• 2025 guidance: Core growth 1% to 3%, adjusted EBITDA margin approximately 14%, EPS between $0.95 and $1.05.
• Restructuring expected to generate roughly $20M of gross annualized savings.
• Board authorized share repurchases of up to $250M over the next two years.
• Guidance assumes FX rates flat with year ending 2024, no significant changes in dental market conditions, and factors in Spark net deferral change, investments, and tax rate.

• Macro uncertainties: Tariffs, foreign exchange rates, interest rates pose risks to the outlook.
• China orthodontic market: Slowdown due to VBP preparations continuing in first half of 2025.
• Diagnostics sector: Contraction, with no compelling evidence yet of increased demand in order book.
• Spark deferral: Modest year-on-year headwind in Q1 2025, but benefit in second half.
• Investments: Impact on adjusted EBITDA margins from investments in businesses like Nobel Biocare, Challenger Implants, etc.

Q: Elizabeth Anderson asked about where Envista could outperform initial expectations and risks to guidance.

A: Paul Keel mentioned potential upside from Spark (taking share/gross margin expansion), Implants (positive growth and progress), and Diagnostics (strong leadership position). Eric Hammes added margin upside from growth, Spark profitability, and G&A costs. Risks include macro tariffs, FX, interest rates.

Q: Jon Block asked about Envista's implant business growth relative to market.

A: Paul Keel said Envista thinks it'll continue to gain momentum in implants, but market conditions similar to 2024; upside if market turns more quickly.

Q: Ahmed Muhammad asked about Spark profitability impact on operating margin and diagnostics bottoming out.

A: Paul Keel said Spark is ~10% of sales, so margin improvement benefits Envista; Eric Hammes said diagnostics expected to be flat to low single-digit growth, with factors like exiting geographies and market improvement contributing.

Q: Jeff Johnson asked about new IOS for diagnostics and Carestream.

A: Paul Keel said there are new product introductions, including additional functionality to IOS and new sensors, with more to be said at dental shows.

Q: Kevin Caliendo asked about Analyst Day and long-term plans.

A: Paul Keel said Analyst Day on March 5th will cover long-term value creation, deeper dive into implants and ortho, reinstated medium-term targets, and management team exposure.

Q: Erin Wright asked about equipment and consumables sell-in/sellout trends and tariffs.

A: Eric Hammes said consumables inventory levels stable, no major comp issues; Paul Keel said well-positioned to respond to tariff uncertainties with local-for-local supply chain.

Q: Unidentified Analyst asked about Spark unit cost improvement and dealer inventory.

A: Paul Keel said continued unit cost improvement via manufacturing technology strategy; Eric Hammes said dealer inventory headwinds in 2024 are expected to be consistent in 2025.

Q: Steven Valiquette asked about EBITDA margin cadence.

A: Eric Hammes said slightly lower margins in first half and slightly better in second half due to Spark deferral, China impact, and gross margin dynamics.

Q: Brandon Vazquez asked about durability of Nobel improvements and Spark profitability path.

A: Paul Keel said improvements due to investments and work, with potential upside from market recovery; Spark profitability driven by manufacturing improvements, share gains, market recovery, and price increases.

Q: Vik Chopra asked about factors affecting top-line guidance range and dental capital equipment environment.

A: Paul Keel said upside from Spark, Implants, and Diagnostics; Eric Hammes said capital equipment environment has DSOs as a big opportunity but sensitive to interest rates.